摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

环氯唑仑 | 58765-21-2

中文名称
环氯唑仑
中文别名
——
英文名称
ciclotizolam
英文别名
4-bromo-7-(2-chlorophenyl)-13-cyclohexyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
环氯唑仑化学式
CAS
58765-21-2
化学式
C20H18BrClN4S
mdl
——
分子量
461.813
InChiKey
ZOSHXIXUCKESEG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    27
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    71.3
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • Diagnostic/therapeutic agents
    申请人:Klaveness Jo
    公开号:US20050002865A1
    公开(公告)日:2005-01-06
    Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.
    可定位的诊断和/或治疗活性剂,例如超声对比剂,包括悬浮在载体液中的报告物,该报告物包含含气体或生成气体的材料,该剂能够与目标形成至少两种结合对。
  • CD38-BINDING CD31 PEPTIDES AND USES THEREOF
    申请人:ENCEFA
    公开号:EP3943505A1
    公开(公告)日:2022-01-26
    The present invention relates to peptides derived from CD31, specifically binding to CD38; and their use in the prevention and/or treatment of diseases.
    本发明涉及从 CD31 衍生的肽,特别是与 CD38 结合的肽;以及它们在预防和/或治疗疾病中的用途。
  • Halogen treatment of heart attack and ischemic injury
    申请人:Fred Hutchinson Cancer Research Center
    公开号:US10201570B2
    公开(公告)日:2019-02-12
    The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.
    本发明涉及卤素化合物(包括化物)和卤代化合物(包括化物、硫化物)在治疗和预防疾病和伤害方面的用途。本发明进一步涉及包含卤素化合物和/或卤化属化合物的组合物,包括药物组合物,以及制造此类化合物和向需要的受试者施用此类组合物的方法。
  • Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
    申请人:Counts David F.
    公开号:US10463611B2
    公开(公告)日:2019-11-05
    The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.
    本公开提供了一种用于口服的每日一次溶性药用活性制剂。在某些实施方案中,该组合物包括掺入小颗粒中的溶性药用活性有机化合物,每个颗粒都有一个溶性药用活性有机化合物或其可接受盐的核心,该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透膜包围,该膜能够延迟其中的药用活性化合物的溶解,并延长药用活性化合物的释放时间。在某些实施方案中,本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时,从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
  • LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
    申请人:Scidose, Llc
    公开号:EP1954244A1
    公开(公告)日:2008-08-13
查看更多

同类化合物

阿帕泛 贝帕泛 苯他西泮 环氯唑仑 溴替唑仑 氯噻西泮 司替帕泛 去甲氯噻西泮; 去甲基氯噻西泮; 5-(2-氯苯基)-7-乙基-1,3-二氢-2H-噻吩并[2,3-e][1,4]二氮杂卓-2-酮 伊拉帕泛 乙替唑仑 alpha-羟基依替唑仑 [(R,S)-4-(4-氯苯基)-2,3,9-三甲基-6H-1-硫杂-5,7,8,9a-四氮杂-环戊环[e]氮杂-6-基]-乙酸叔丁酯 PROTACBET结合部分2 N-(4-叔-丁基苯基)-6-(2-氯苯基)-1-甲基-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲酰胺 7-氯-5-(2-氯苯基)-1,3-二氢-2H-噻吩并-(2,3-e)-(1,4)-二氮杂卓-2-硫酮 7-乙基-5-苯基-3,4-二氢噻吩并[3,2-f][1,4]二氮杂卓-2-酮 7-乙基-5-(2-氟苯基)-1,3-二氢-2H-噻吩并[2,3-e]-1,4-二氮杂卓-2-酮 6-(2-氯苯基)-1-甲基-N-[4-(三氟甲基)苯基]-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲硫代酰胺 6-(2-氯苯基)-1-甲基-N-(1-甲基-2-苯基乙基)-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲硫代酰胺 5-(2-氯苯基)-7-乙基-1H-噻吩并[2,3-e][1,4]二氮杂卓-2(3h)-硫酮 5-(2-氯苯基)-2,3-二氢-2-氧代-1H-噻吩并[2,3-e]-1,4-二氮杂卓-7-丙酸甲酯 5,6-二氢-5-甲基-6-氧代-4H-i咪唑并[1,5-a]噻吩并[2,3-f][1,4]二氮杂-3-羧酸1,1-二甲基乙酯 4-甲基-3,4-二氢-1H-噻吩并[2,3-E][1,4]二氮杂-2,5-二酮 4-(2-氯苯基)-N-(2-羟基乙基)-9-甲基-6H-噻吩并(3,2-f)(1,2,4)三唑并(4,3-a)(1,4)二氮杂卓-2-丙酰胺 4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-丙酸甲酯 4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-丙酸 4-(2-氯苯基)-9-甲基-2-(4-吗啉-4-基-4-羰基丁基)-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓 3-噻丁烷酮,2-氯-2-(1-甲基乙基)- 3-[4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-基]-2-丙炔-1-醇 2-((6R)-4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F]的[1,2,4 1H-噻吩并[2,3-e]-1,4-二氮杂卓-2,3-二酮,1-甲基-5-苯基-,3-肟 (S)-4-(4-氯苯基)-N-(4-羟基苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-乙酰胺 (S)-2-(5-(4-氯苯基)-6,7-二甲基-2-氧代-2,3-二氢-1H-噻吩并[2,3-E] (S)-2-(4-(4-氯苯基)-2-(羟甲基)-3,9-二甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3]-A][1,4]二氮杂卓-6-基)乙酸甲酯 (S)-(+)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)乙酸叔丁酯 (-)-JQ-1; (R)-(-)2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂环庚烷-6-基)乙酸叔丁酯 (+)-JQ1羧酸 tetrahydro-furan-3-carboxylic acid [7-bromo-5-(2-chloro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-ylidene]-hydrazide 2-Bromo-4-(2-chloro-phenyl)-8-methyl-6H,8H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-9-one 4-(2-chloro-phenyl)-2-ethyl-9-oxo-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxylic acid methylamide piperidine-4-carboxylic acid [7-bromo-5-(2-chloro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-ylidene]-hydrazide 9-(2-chlorophenyl)-3-methyl-17-thia-2,4,5,8-tetrazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,11(16)-tetraene N,N-Diethyl-N'-thieno[3,2-b]pyrrolizin-(4Z)-ylidene-propane-1,3-diamine 2-bromo-4-(2-chloro-phenyl)-9-tetrahydrofuran-3-yl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 5-(2-chloro-phenyl)-1,6,7-trimethyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 4-(2-Chlorophenyl)-6H-thieno<3,2-f>-1,2,4-triazolo<4,3-a>-1,4-diazepine 4-(2-Chloro-phenyl)-9-cyclopropyl-2-iodo-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulene Acetic acid 5-(2-chloro-phenyl)-7-ethyl-2-oxo-2,3-dihydro-1H-thieno[2,3-e][1,4]diazepin-3-yl ester Acetic acid 5-(2-chloro-phenyl)-7-ethyl-1-methyl-2-oxo-2,3-dihydro-1H-thieno[2,3-e][1,4]diazepin-3-yl ester 2-ethyl-4-phenyl-6H-imidazo[1,2-a]thieno[3,2-f][1,4]diazepine